Secondary prevention following coronary intervention. Survey of 13 interventional centres in Austria;Sekundarpravention nach koronarintervention. Vorgangsweise an 13 interventionellen zentren in Osterreich

Wiener Klinische Wochenschrift

Volumn 111, Issue 16, 1999, Pages 643-649

  Drexel, Heinz ^a   Gaul, Georg Bernhard ^b   Grimm, Georg ^c   Klein, Werner ^d   Kleemann, Lucas ^e   Leisch, Franz ^f   Mlczoch, Johannes ^g   Pichler, Max ^h   Sailer, Sigurd ⁱ   Slany, Jörg ^j   Steinbach, Konrad ^k   Tragl, Karl Heinz ^l   Mori, Michal ^m   Kühn, Peter ^m,n  

^a Landeskrankenhaus Feldkirch   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c GENERAL HOSPITAL KLAGENFURT   (Austria)

^d UNIVERSITY HOSPITAL GRAZ   (Austria)

^e A ö KH Krems   (Austria)

^f KEPLER UNIVERSITY HOSPITAL   (Austria)

^g III Med Abt Stoffwechselerkr N   (Austria)

^h Rehabilitationszentrum Grossgmain   (Austria)

ⁱ Salzburger Landeskliniken   (Austria)

^j Krankenanstalt Stadt Wien R   (Austria)

^k WILHELMINEN HOSPITAL   (Austria)

^l DANUBE HOSPITAL   (Austria)

^m KH Barmherzige Schwestern Linz   (Austria)

ⁿ NONE   (Austria)

more..

Author keywords

Betablocker; Coronary artery disease; PTCA; Secondary prevention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; STATIN; TICLOPIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANGINA PECTORIS; ARTICLE; AUSTRIA; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIET; HEART INFARCTION; HUMAN; HYPERTENSION; NORMAL HUMAN; PRACTICE GUIDELINE; SECONDARY PREVENTION; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; RECURRENT DISEASE; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AUSTRIA; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; QUESTIONNAIRES; RECURRENCE; RISK FACTORS;

EID: 0033520170     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. European Society of Cardiology survey of secondary prevention of coronary heart disease (1997) Principal results. EUROASPIRE Study group. Eur Heart J 18/10: 1569-1582
2. Aspire Steering Group (1996) A British Cardiac Society survey of potential for the secondary prevention of coronary disease: ASPIRE (Action on secondary prevention through intervention to reduce events). Heart 75: 334-341
3. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE (1996) Adjunctive drug therapy of acute myocardial infarction - Evidence from clinical trials. N Engl J Med 335/22: 1660-1667
4. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106
5. The Multicentre Anti-Atheroma Study (MAAS) (1994) Effect of simvastatin on coronary atheroma. Lancet 344: 633
6. Sacks FM. Pfeffer MA, Moye LA, Rouleau JL, Rutherford JL, Cole TG, et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335/14: 1001-1009
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339/19: 1349-1357
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333/20: 1301-1307
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327/10: 669-677
10. The SOLVD Investiators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325/5: 293-302
11. Gohlke H, Mathes P, Fleck E, Keil U, Rost R (1997) Empfehlungen zur umfassenden Risikoverringerung für Patienten mit koronarer Herzerkrankung. Z Kardiol 86: 776-777
12. Risk-Reduction Therapy (1996) The challenge to change: Presented at the 68th Scientific Sessions of the American Heart Association. November 13, 1995 Anaheim, California. Circulation 93: 2205-2211
13. Wood D (1998) Prevention of coronary heart disease in clinical practice; recommendations of the second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 19: 1434-1503
14. Työrälä K, De Bakker G, Graham I, Poole-Wilson PA, Wood D on behalf of the task force (1994) Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15: 1300-1331
15. Kühn P (1996) Hand aufs Herz (Zusammenfassung der Guidelines der ESC). Österr Ärztezeitung 19: 28-33